Kishnani, P. S. Et Al. 2023. Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurology , vol.80, no.6 , 558-567.

Kishnani, P. S., Diaz-Manera, J., Toscano, A., Clemens, P. R., Ladha, S., Berger, K. I., ... Kushlaf, H.(2023). Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks: A Phase 3 Randomized Clinical Trial. JAMA Neurology , vol.80, no.6, 558-567.

Kishnani, Priya Et Al. "Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks: A Phase 3 Randomized Clinical Trial," JAMA Neurology , vol.80, no.6, 558-567, 2023

Kishnani, Priya S. Et Al. "Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks: A Phase 3 Randomized Clinical Trial." JAMA Neurology , vol.80, no.6, pp.558-567, 2023

Kishnani, P. S. Et Al. (2023) . "Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks: A Phase 3 Randomized Clinical Trial." JAMA Neurology , vol.80, no.6, pp.558-567.

@article{article, author={Priya S. Kishnani Et Al. }, title={Efficacy and Safety of Avalglucosidase Alfa in Patients with Late-Onset Pompe Disease after 97 Weeks: A Phase 3 Randomized Clinical Trial}, journal={JAMA Neurology}, year=2023, pages={558-567} }